Cannabinoids and anxiety

Reading this collection

Dose direction matters more here than in most areas: the literature on cannabinoids and anxiety includes biphasic effects, where the response at one dose does not predict the response at another. Any reading of these studies has to keep dose and preparation in view.

Several records concern the endocannabinoid system's role in stress regulation rather than an anxiety diagnosis as such. They are mechanistic context, not clinical endpoints.

The evidence in this library

5 source-linked studies — 3 scientific source · 1 peer-reviewed review · 1 guideline / official boundary. Each links to its source; identifiers are shown where the record carries them.

1. Clinical and Cognitive Improvement Following Full-Spectrum CBD for Anxiety

   2022 · Nature · CBD, Full Spectrum

   Scientific source

2. Cannabidiol as a Potential Treatment for Anxiety Disorders

   2015 · PubMed · CBD

   Peer-reviewed review

   PMID 26341731

3. CBD for Anxiety Disorders: Systematic Review and Meta-analysis

   PubMed · CBD

   Guideline / official boundary

   PMID 36370842

4. ECS Role in Stress Response and HPA Axis Regulation

   PubMed · CBD, THC, ECS

   Scientific source

   PMID 31006082

5. Nardostachys jatamansi (Jatamansi): Anxiolytic via GABA Modulation

   PubMed · Jatamansi

   Scientific source

   PMID 29934858

How to read this evidence

These are the boundaries recorded against the studies above, reproduced as written in the library:

• Supportive symptom research; avoid guaranteed anxiolytic, sedative, or psychiatric treatment claims.
• Preclinical/early clinical anxiety research.
• Use as evidence-informed ECS/cannabinoid research navigation; avoid product-specific disease claims.